{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:19:43Z","timestamp":1758586783612,"version":"3.44.0"},"reference-count":30,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["OPTH"],"DOI":"10.2147\/opth.s545516","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:55:11Z","timestamp":1758524111000},"page":"3497-3504","source":"Crossref","is-referenced-by-count":0,"title":["Aganirsen as a Therapeutic Alternative for Modulating Corneal Neovascularization: A Real-World Case Series Study"],"prefix":"10.2147","volume":"Volume 19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6016-9284","authenticated-orcid":true,"given":"Salvador","family":"Garc\u00eda-Delpech","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Fathi Nieto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Herv\u00e1s Ontiveros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5241-0066","authenticated-orcid":true,"given":"Patricia","family":"Udaondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damian","family":"Garcia-Teillard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2025,9]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"108363","DOI":"10.1016\/j.exer.2020.108363","volume":"202","author":"Nicholas","year":"2021","journal-title":"Exp Eye Res"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"S354","DOI":"10.4103\/IJO.IJO_3043_23","volume":"72","author":"Wu","year":"2024","journal-title":"Indian J Ophthalmol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1097\/00055735-200108000-00002","volume":"12","author":"Chang","year":"2001","journal-title":"Curr Opin Ophthalmol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/01.icl.00000117256.77329.06","volume":"30","author":"Nomura","year":"2004","journal-title":"Eye Contact Lens"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1038\/nm0909-993","volume":"15","author":"Skobe","year":"2009","journal-title":"Nat Med"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/s0039-6257(98)00035-6","volume":"43","author":"Lee","year":"1998","journal-title":"Surv Ophthalmol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"733538","DOI":"10.3389\/fmed.2021.733538","volume":"8","author":"Lasagni Vitar","year":"2021","journal-title":"Front Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3109\/08830185.2012.737877","volume":"32","author":"Niederkorn","year":"2013","journal-title":"Int Rev Immunol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1136\/bjophthalmol-2020-316705","volume":"105","author":"Alio","year":"2021","journal-title":"Br J Ophthalmol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1016\/j.ophtha.2010.01.039","volume":"117","author":"Bachmann","year":"2010","journal-title":"Ophthalmology"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1016\/j.transproceed.2007.08.020","volume":"39","author":"Sellami","year":"2007","journal-title":"Transplant Proc"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1097\/ICO.0b013e31819c4e55","volume":"28","author":"Garcia","year":"2009","journal-title":"Cornea"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"15","DOI":"10.22336\/rjo.2019.4","volume":"63","author":"Sharif","year":"2019","journal-title":"Rom J Ophthalmol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1097\/ICO.0b013e318201405a","volume":"30","author":"Gupta","year":"2011","journal-title":"Cornea"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"5479","DOI":"10.3390\/ijms25105479","volume":"25","author":"Drzyzga","year":"2024","journal-title":"Int J Mol Sci"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.survophthal.2012.01.007","volume":"57","author":"Chang","year":"2012","journal-title":"Surv Ophthalmol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"5778","DOI":"10.1167\/iovs.10-6816","volume":"52","author":"Hos","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/bjo.2011.204701","volume":"96","author":"Cursiefen","year":"2012","journal-title":"Br J Ophthalmol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ymthe.2003.10.003","volume":"9","author":"Rabinovsky","year":"2004","journal-title":"Mol Ther"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1124\/jpet.108.147496","volume":"329","author":"Al-Mahmood","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"4072","DOI":"10.1167\/iovs.05-0105","volume":"46","author":"Berdugo","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref22","unstructured":"Commission of the European Communities of 17-IV-2007 related to the medicinal product \u201cAntisense Oligonucleotide (TATCCGGAGGGCTCGCCATGCTGCT)\u201d is designated as an orphan medicinal product for the indication: prevention of corneal graft rejection. It shall be entered in the community register of orphan medicinal products under number EU\/3\/07\/445."},{"key":"ref23","unstructured":"U.S. Food & Drug Administration. U.S. Department of Health & Human Services. Orphan Drug Designation and Approval. Available from: https:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/detailedIndex.cfm?cfgridkey=500515. Accessed September 19, 2025."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/j.ophtha.2009.04.016","volume":"116","author":"Cursiefen","year":"2009","journal-title":"Ophthalmology"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1016\/j.ophtha.2014.03.038","volume":"121","author":"Cursiefen","year":"2014","journal-title":"Ophthalmology"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1167\/iovs.11-9064","volume":"53","author":"Cloutier","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/s1542-0124(11)70035-0","volume":"9","author":"Keating","year":"2011","journal-title":"Ocul Surf"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"7337","DOI":"10.12998\/wjcc.v11.i30.7337","volume":"11","author":"Lai","year":"2023","journal-title":"World J Clin Cases"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1097\/IAE.0b013e318206cf4b","volume":"31","author":"Yasuda","year":"2011","journal-title":"Retina"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"190","DOI":"10.17925\/EOR.2012.06.03.190","volume":"6","author":"Bainbridge","year":"2012","journal-title":"Eur Ophthalmic Rev"}],"container-title":["Clinical Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/article\/download\/107202","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/article\/download\/107202","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:55:12Z","timestamp":1758524112000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/aganirsen-as-a-therapeutic-alternative-for-modulating-corneal-neovascu-peer-reviewed-fulltext-article-OPTH"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":30,"URL":"https:\/\/doi.org\/10.2147\/opth.s545516","relation":{},"ISSN":["1177-5483"],"issn-type":[{"value":"1177-5483","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]}}}